In response to the COVID-19 pandemic, countless healthcare organizations across the world have adopted or expanded new methods of delivering care virtually; these include telemedicine appointments, remote patient monitoring, and even virtual assistants.
To continue collaborating and supporting healthcare providers and patients, pharmaceutical companies are also undergoing rapid digital transformation within their engagement strategies and pharmacovigilance processes.
Generally, pharmacovigilance is concerned with drug safety, but there are several niche disciplines within, such as operations, surveillance, systems, and designated 'qualified persons responsible for pharmacovigilance' (QPPVs). The life sciences professionals in these various roles contribute to the expansive process of collecting, analyzing, monitoring, and preventing medication-induced adverse events.
Several common challenges routinely surface during the execution and maintenance of this process. Amid the COVID-19 pandemic, these particular challenges have been further amplified, including:
Communication of general drug information to healthcare providers (HCPs), as well as reports and other analyses that can better assist in the detection and monitoring of adverse events.
While the chatbot continues to assist in educating and supporting healthcare providers, this new feature positions the virtual assistant to distinguish an adverse event and trigger the designated reporting and escalation flow.